What continuous glucose monitoring actually changes for type 2 diabetes

For most of the last two decades, a person with type 2 diabetes learned about their glucose four times a year, from a single HbA1c number. That number is an average. It hides the mornings that spike, the afternoons that crash, and the meals that quietly undo a week of effort.

Continuous glucose monitoring replaces the average with a curve. A small sensor worn on the arm samples interstitial glucose every few minutes and streams it to a phone. What clinicians gain is not just more data but a different kind of conversation: instead of asking a patient to recall what they ate, we look at the same graph together.

The trial evidence is genuinely encouraging. Randomised studies in non-insulin-treated type 2 diabetes have shown HbA1c reductions in the range of 0.3 to 0.6 percentage points at six months — modest on paper, but achieved largely through behaviour change rather than added medication.

Where the enthusiasm outruns the evidence is in healthy users without diabetes. Glucose variability in a metabolically healthy person is normal, and treating every post-meal rise as a problem to be optimised away has no outcome data behind it. It does have a real cost: anxiety, and food rules that are hard to unlearn.

Our recommendation on HealthSpire is deliberately narrow. If you are managing type 2 diabetes, a two-week sensor period twice a year, reviewed with your clinician, is usually enough to find your patterns. Continuous wear helps most when insulin is involved or when hypoglycaemia is a live risk.